Last reviewed · How we verify
epidermal growth factor
Epidermal growth factor (EGF) binds to and activates the epidermal growth factor receptor (EGFR) on cell surfaces, promoting cell proliferation, differentiation, and survival.
Epidermal growth factor (EGF) binds to and activates the epidermal growth factor receptor (EGFR) on cell surfaces, promoting cell proliferation, differentiation, and survival. Used for Wound healing and tissue repair, Burn injuries, Chronic wounds.
At a glance
| Generic name | epidermal growth factor |
|---|---|
| Also known as | Epidermal Growth Factor Serum |
| Sponsor | Chinese PLA General Hospital |
| Drug class | Growth factor |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Biologic |
| Therapeutic area | Dermatology, Wound Healing, Tissue Repair |
| Phase | FDA-approved |
Mechanism of action
EGF is a naturally occurring polypeptide growth factor that stimulates cellular growth and proliferation by binding to EGFR, a receptor tyrosine kinase. This interaction triggers intracellular signaling cascades that promote wound healing, tissue repair, and epithelial cell regeneration. The marketed formulation is typically used topically or systemically to accelerate healing of damaged tissues and wounds.
Approved indications
- Wound healing and tissue repair
- Burn injuries
- Chronic wounds
- Corneal ulcers and ocular surface disease
Common side effects
- Local irritation or erythema at application site
- Allergic reactions
- Infection risk at wound site
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (PHASE1)
- A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |